Iberdomide plus daratumumab/dexamethasone met the second dual primary end point of the phase 3 EXCALIBER-RRMM trial in relapsed/refractory multiple myeloma.
|Poll|January 25, 2016
Testicular Lesion Detected in 23-Year-Old Man
Author(s)Cesar A. Moran, MD
A 23-year-old young man presents with a testicular lesion. After assessing the lesion, a biopsy is performed. What is your diagnosis?
Advertisement
A 23-year-old young man presents with a testicular lesion. According to the histopathology image below, what is your diagnosis?
What is your diagnosis?
Advertisement
Related to this article
Melody Rasouli, MD, MBA, FACOG, explained how random-start ovarian stimulation and rapid sperm banking fit fertility preservation into cancer care.
SurVaxM, a cancer vaccine, missed statistical significance for overall survival in patients with newly diagnosed glioblastoma in the SURVIVE trial.
Veronika Bachanova, MD, PhD, discussed how the favorable safety profile of CAR natural killer cell therapies may come with trade-offs in persistence and response durability.
“What we have here, I believe, is a strong signal that there is a population…who will benefit from chemotherapy,” said Mark D. Hurwitz, MD, FASTRO, FACRO.
Experts discuss data from the MonumenTAL-3 trial and the evolving roles of talquetamab and other bispecific antibodies in relapsed/refractory multiple myeloma.
Data from the phase 3 HER2CLIMB-05 study support the FDA approval of tucatinib-based maintenance treatment in HER2-positive metastatic breast cancer.
PRV111 eliminated planned surgery in 100% of evaluable patients with non-invasive oral cancer or high-grade dysplasia.
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Tucatinib Combo as Maintenance in HER2+ Breast Cancer
2
Novel Cancer Vaccine Plus Temozolomide Miss Primary End Point in Glioblastoma
3
Personalized Vaccines May Have Utility Across All Lung Cancer Stages
4
Considering Talquetamab and Emerging Bispecifics in R/R Multiple Myeloma
5